GURUFOCUS.COM » STOCK LIST » USA » NAS » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Return-on-Tangible-Asset
Switch to:

Ligand Pharmaceuticals (NAS:LGND) Return-on-Tangible-Asset

: -21.64% (As of Dec. 2022)
View and export this data going back to 1995. Start your Free Trial

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Ligand Pharmaceuticals's annualized Net Income for the quarter that ended in Dec. 2022 was $-69.9 Mil. Ligand Pharmaceuticals's average total tangible assets for the quarter that ended in Dec. 2022 was $323.3 Mil. Therefore, Ligand Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2022 was -21.64%.

The historical rank and industry rank for Ligand Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

LGND' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -7.64   Med: 9.5   Max: 73.61
Current: -7.64

During the past 13 years, Ligand Pharmaceuticals's highest Return-on-Tangible-Asset was 73.61%. The lowest was -7.64%. And the median was 9.50%.

LGND's Return-on-Tangible-Asset is ranked better than
78.17% of 1576 companies
in the Biotechnology industry
Industry Median: -37.98 vs LGND: -7.64

Ligand Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Ligand Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.75 60.16 -0.34 8.33 -6.01

Ligand Pharmaceuticals Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Return-on-Tangible-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.29 -10.44 -0.98 0.46 -21.64

Competitive Comparison

For the Biotechnology subindustry, Ligand Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Ligand Pharmaceuticals Return-on-Tangible-Asset Distribution

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Return-on-Tangible-Asset falls in comparison to its industry or sector. The grey bar indicates the Return-on-Tangible-Asset's extreme value range as defined by GuruFocus.



Ligand Pharmaceuticals Return-on-Tangible-Asset Calculation

Ligand Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-33.361/( (805.116+304.358)/ 2 )
=-33.361/554.737
=-6.01 %

Ligand Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2022 )  (Q: Sep. 2022 )(Q: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2022 )  (Q: Sep. 2022 )(Q: Dec. 2022 )
=-69.94/( (342.181+304.358)/ 2 )
=-69.94/323.2695
=-21.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2022) net income data.


Ligand Pharmaceuticals  (NAS:LGND) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Ligand Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals (NAS:LGND) Business Description

Ligand Pharmaceuticals logo
Traded in Other Exchanges
Address
5980 Horton Street, Suite 405, Emeryville, CA, USA, 94608
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Executives
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
Andrew Reardon officer: See Remarks C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza officer: Chief Financial Officer C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
Jason Haas director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Sarah Boyce director C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Nancy Ryan Gray director C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
Matthew E Korenberg officer: VP, Finance and CFO 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Melanie J Herman officer: Director of Accounting 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Investment 10 Llc other: See Explanation of Responses C/O GROSVENOR CAPITAL MANAGEMENT LP, 900 N. MICHIGAN AVENUE, SUITE 1100, CHICAGO IL 60611
Nishan M Desilva officer: VP, Corporate Development 11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Matthew W Foehr officer: EVP and COO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454

Ligand Pharmaceuticals (NAS:LGND) Headlines

Other Sources